Aprea Therapeutics Reports Promising Results for APR-1051 Trials
Company Announcements

Aprea Therapeutics Reports Promising Results for APR-1051 Trials

Aprea Therapeutics ( (APRE) ) just unveiled an announcement.

Aprea Therapeutics has announced promising preliminary safety results for its WEE1 inhibitor, APR-1051, showcased at an international oncology conference. The Phase 1 trial indicates APR-1051 is safe and well-tolerated without serious side effects, presenting potential as a treatment for advanced solid tumors. With ongoing trials in the U.S., the company is optimistic about further exploring APR-1051’s therapeutic potential, aiming for more efficacy data in 2025.

See more insights into APRE stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAprea Therapeutics reports Q3 EPS (64c) vs (86c) last year
TheFlyAprea Therapeutics presents preliminary results on APR-1051
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App